Insight Molecular Diagnostics Inc. (IMDX) AI Stock Analysis
IMDX AI stock analysis summary
AI ResearchInsight Molecular Diagnostics Inc. (IMDX) is a precision diagnostics company developing cancer monitoring and transplant rejection assays. In FY2025, revenue increased 115.6% to $4.1M, while net income was -$50.2M and operating cash flow was -$22.2M. Over the trailing twelve months, revenue was $1.7M, and the stock is down 59.9% year-to-date.
- Market cap
- $98.5M
- Revenue (TTM)
- $1.7M
- P/E
- —
- 1Y return
- -34.9% S&P 500 16.8%
- Avg. target
- $8.25 174.1% vs last close
Bull case
- Wall Street analysts have a mean price target of $8.25, representing a 174.1% premium over the last close of $3.01.
- Annual revenue expanded 115.6% in FY2025 to $4.1M, supported by a 5-year revenue CAGR of 27.2%.
- The company maintains net cash of $15.1M, with $17.8M in cash and short-term investments against $2.6M in total debt as of June 30, 2026.
Bear case
- Free cash flow was -$25.4M in FY2025, and shareholders' equity stood at -$21.3M as of June 30, 2026.
- Quarterly revenue fell 53.9% year-over-year in the latest quarter ending June 30, 2026, bringing trailing twelve months revenue down to $1.7M.
- Significant dilution has occurred, as the 5-year share count increased 818.8%.
What Insight Molecular Diagnostics does
Insight Molecular Diagnostics Inc. operates as a precision diagnostics company developing laboratory developed tests, kitted research use only tests, and kitted clinical tests. Its oncology pipeline includes DetermaCNI, a blood-based monitoring tool detecting progression after cancer treatment, and DetermaIO, a gene expression test predicting response to immunotherapies. For transplant monitoring, the company offers GraftAssureCore, GraftAssureIQ, and GraftAssureDx to assess donor-derived cell-free DNA. It also provides testing services for biomarker discovery, assay design, and clinical trial support, and maintains a collaboration agreement with Bio-Rad Laboratories, Inc. for transplant diagnostic products.
Growth and profitability
Between FY2021 and FY2025, annual revenue rose from $2.2M to $4.1M, generating a 5-year revenue CAGR of 27.2%. In FY2025, revenue grew 115.6% to $4.1M, while gross margin was 4.7% and operating margin was -754.1%. Net income for FY2025 was -$50.2M compared to -$60.7M in FY2024. For the trailing twelve months ending June 30, 2026, revenue stood at $1.7M with an operating margin of -3815.1% and diluted EPS of -$1.52. In the latest quarter, quarterly revenue fell 53.9% year-over-year.
Balance sheet and cash flow
As of June 30, 2026, the company held $17.8M in cash and short-term investments against total debt of $2.6M, resulting in net cash of $15.1M. Total assets stood at $29.4M, and the current ratio was 2.00. Shareholders' equity was -$21.3M, indicating negative equity. In FY2025, operating cash flow was -$22.2M and free cash flow was -$25.4M, with capital expenditures of $3.2M. Over the past five years, the company's share count increased 818.8%.
Valuation and performance
At a last close of $3.01 on October 16, 2026, Insight Molecular Diagnostics had a market cap of $98.5M and an enterprise value of $113.0M. The stock trades at a price-to-sales multiple of 59.0x and an EV-to-revenue multiple of 67.7x, compared to a median price-to-sales multiple of 4.1x for its US-listed Healthcare peers. Its price-to-book ratio is 87.1x. Over the past year, IMDX shares fell 34.9%, while the S&P 500 (SPY) gained 16.8%. Over five years, the stock fell 95.6% compared to an 83.0% gain for the benchmark.
What analysts expect
Wall Street coverage consists of 2 Strong Buy, 1 Buy, and 2 Hold ratings, with 0 Sell or Strong Sell ratings. The mean price target is $8.25, which is 174.1% above the last close of $3.01. For the fiscal year ending December 31, 2026, consensus estimates project revenue of $966,200 and EPS of -$0.93. For the following fiscal year, 2 analysts forecast revenue of $6.7M and EPS of -$0.80. The company beat EPS estimates in 2 of the last 4 quarters, and its next earnings date is November 9, 2026.
Key risks and what to watch
- Ongoing cash burn could deplete cash and short-term investments of $17.8M following FY2025 free cash flow of -$25.4M.
- Operating losses remain elevated, highlighted by a trailing twelve months operating margin of -3815.1%.
- Stock volatility is high, with a beta of 1.80 and a year-to-date share price decline of 59.9%.
AI-generated research summary. Written with AI from Quotelinks data as of October 16, 2026 and checked so every figure matches that data. For information only, not investment advice. Disclaimer
About this IMDX AI stock analysis
This page is an AI-written research summary of Insight Molecular Diagnostics Inc. (IMDX). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.
Related: IMDX income statement, IMDX balance sheet, IMDX key metrics, IMDX analyst forecast, IMDX chart. See the IMDX stock overview for the latest quote and news.
IMDX AI stock analysis FAQ
What is Insight Molecular Diagnostics' ticker and previous name?
The company trades on the NASDAQ under the ticker IMDX. It was previously named OncoCyte Corporation before changing its name in June 2025.
Does IMDX pay a dividend?
Insight Molecular Diagnostics does not pay a dividend.
What is the consensus analyst price target for IMDX?
The mean price target is $8.25, which is 174.1% higher than the last close of $3.01.
How much cash and debt does IMDX hold?
As of June 30, 2026, the company held $17.8M in cash and short-term investments and $2.6M in total debt, resulting in net cash of $15.1M.
When is Insight Molecular Diagnostics' next earnings date?
The company's next earnings report is scheduled for November 9, 2026.